Lineage Cell Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(IN THOUSANDS, EXCEPT PER SHARE DATA)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| REVENUES: | ||
| Collaboration revenues | $1,270 | $1,187 |
| Royalties, license and other revenues | 232 | 257 |
| Total revenues | 1,502 | 1,444 |
| OPERATING EXPENSES: | ||
| Cost of sales | 36 | 98 |
| Research and development | 3,114 | 3,010 |
| General and administrative | 4,857 | 4,997 |
| Total operating expenses | 8,007 | 8,105 |
| Loss from operations | (6,505) | (6,661) |
| OTHER INCOME (EXPENSES): | ||
| Interest income, net | 478 | 462 |
| Loss on marketable equity securities, net | (5) | (5) |
| Change in fair value of warrant liability | 2,305 | — |
| Foreign currency transaction loss, net | (231) | (354) |
| Other income (expense), net | (185) | — |
| Total other income (expenses) | 2,362 | 103 |
| NET LOSS | (4,143) | (6,558) |
| Net loss attributable to noncontrolling interest | 4 | 16 |
| NET LOSS ATTRIBUTABLE TO LINEAGE | $(4,139) | $(6,542) |
| Net loss per common share attributable to Lineage basic and diluted | $(0.02) | $(0.04) |
| Weighted-average common shares used to compute basic and diluted net loss per common share | 226,054 | 182,909 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.